GlassScriptPhysician profile
Michael Thomas Ginnetti
NPI 1316474976
$4,561.93
in general payments reported to CMS, 2019-2025
26 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.00 · 2022: $184 · 2023: $830 · 2024: $1,974 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773 · Education: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.47 |
| Education | $551.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,108.88 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $836.91 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $399.95 | 2023-2025 | Ilumya |
| Lilly USA, LLC | $284.50 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $245.94 | 2022-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $205.61 | 2023-2025 | Puraply Am, Novachor, Puraply Wound Matrix |
| Dermavant Sciences, INC. | $183.63 | 2023-2024 | Vtama |
| Organon LLC | $173.91 | 2025 | Vtama |
| Abbvie INC. | $171.69 | 2022-2025 | |
| Pfizer INC. | $131.16 | 2022-2024 | |
| Genzyme Corporation | $108.37 | 2023-2025 | |
| Amgen INC. | $106.77 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $90.69 | 2024-2025 | Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.46 | 2023-2025 | Arazlo, Jublia, Cabtreo |
| Biofrontera INC. | $66.71 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $55.08 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Smith+Nephew, INC. | $45.93 | 2023-2024 | Grafix Pl |
| Novartis Pharmaceuticals Corporation | $39.98 | 2022-2025 | |
| Journey Medical Corporation | $33.57 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $33.00 | 2024 | Sotyktu |
| Incyte Corporation | $29.20 | 2024 | Opzelura |
| Revance Therapeutics, INC. | $24.50 | 2024 | Daxxify |
| Epi Health, LLC | $22.64 | 2022 | |
| Strata Skin Sciences, INC. | $20.79 | 2025 | Xtrac |
| Leo Pharma INC. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ginnetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.